Nagelpilz ist Gegenstand weitreichender wissenschaftlicher Studien. Fachärzte und Dermatologen aus der ganzen Welt waren an wissenschaftlichen Untersuchungen zum Thema Nagelpilz beteiligt. Einige führende Wissenschaftler, die Studien zu Nagelpilz und Erkrankungen der Haut im Allgemeinen durchführten, stellen wir Ihnen hier vor.

Richard Pollak

Aktuelle Beschäftigung:

            Mitarbeiter der Universität Texas in San Antonio

Fachgebiete:

Durchführung von zahleichen wissenschaftlichen Studien zum Thema Nagelpilz.

Veröffentlichungen:

• Pollak, RA, Ilie, C.: Long-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole. J Drugs Dermatol. 2017 Dec 1;16(12):1269-1273.
• Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, Herz-Ruelas ME, Jones TM, Jarratt MT, Pollak RA, Zane LT: The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis. J Drugs Dermatol. 2014 Sep;13(9):1124-32.
• Pollak RA, Siu WJJ, Tatsumi Y, Pillai R: Efinaconazole Topical Solution, 10%: Factors Contributing to Onychomycosis Success. J Fungi (Basel). 2015 Jul 3;1(2):107-114. doi: 10.3390/jof1020107.
• Pollak R, Billstein SA.: Safety of oral terbinafine for toenail onychomycosis. J Am Podiatr Med Assoc. 1997 Dec;87(12):565-70. doi: 10.7547/87507315-87-12-565.
• Pollak RA.: Efinaconazole topical solution, 10%: the development of a new topical treatment for toenail onychomycosis. J Am Podiatr Med Assoc. 2014 Nov;104(6):568-73. doi: 10.7547/8750-7315-104.6.568.
• Pollak R, Billstein SA.: Safety of oral terbinafine for toenail onychomycosis. J Am Podiatr Med Assoc. 1997 Dec;87(12):565-70. doi: 10.7547/87507315-87-12-565.
• Pollak R, Billstein SA.: Efficacy of terbinafine for toenail onychomycosis. A multicenter trial of various treatment durations. J Am Podiatr Med Assoc. 2001 Mar;91(3):127-31. doi: 10.7547/87507315-91-3-127.
• Elewski B, Pollak R, Ashton S, Rich P, Schlessinger J, Tavakkol A: A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol. 2012 Feb;166(2):389-98. doi: 10.1111/j.1365-2133.2011.10660.x. Epub 2011 Dec 6.
• Elewski BE, Rich P, Pollak R, Pariser DM, Watanabe S, Senda H, Ieda C, Smith K, Pillai R, Ramakrishna T, Olin JT: Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013 Apr;68(4):600-608. doi: 10.1016/j.jaad.2012.10.013. Epub 2012 Nov 20.

David M. Pariser, M.D.

Aktuelle Beschäftigung:

Praktizierender Hautarzt, Abschluss Universität Pennsylvania, Philadelphia in Norfolk, Virginia, im Jahr 2009 zum Vorsitzenden der Amerikanischen Akademie für Dermatologie gewählt.

Fachgebiete:

            Hautkrankheiten, Dermatapathologie

Veröffentlichungen:

• James G. Krueger, David Pariser, Stephen K. Tyring,Andrew Blauvelt: 15340 Long-term treatment with secukinumab led to sustained clinical improvement and normalization of inflammatory markers in patients with psoriasis; Dez. 2020
• James G. Krueger, David Pariser, Elisa Muscianisi, Andrew F. Alexis: 15354 Response to treatment with secukinumab in obese patients with moderate to severe psoriasis; Dez. 2020
• Linda Stein Gold, Mark Lebwohl, Kim Papp, David Berk: Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study; Oktober 2020
• Matthias Augustin, D. Thaci, K. Eyerich, K. Reich: The efficacy of secukinumab with continued use in the treatment of psoriasis; Januar 2020
• Eric Simpson, Laurent Eckert, Abhijit Gadkari, David Pariser: Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. November 2019
• Phoebe Rich, Nathaniel I. Jellinek, David M. Pariser: Management Strategies for Onychomycosis in Special Patient Populations. Juni 2015
• Melodie S. Young, David M. Pariser, Phoebe Rich, Nathaniel J. Jellinek: Making Strides in Preventing Onychomycosis Recurrence. Juni 2015
• David Pariser: The Rationale for Renewed Attention to Onychomycosis. Juni 2013
• Richard Scher, Phoebe Rich, David Pariser, Boni Elewski: The Epidemiology, Etiology, and Pathophysiology of Onychomycosis. Juni 2013
• Boni Elewski, David Pariser, Phoebe Rich, Richard Scher: Current and Emerging Options in the Treatment of Onychomycosis. Juni 2013
• David Pariser, Richard Scher, Boni Elewski, Phoebe Rich: Promoting and Maintaining or Restoring Healthy Nails: Practical Recommendations for Clinicians and Patients. Juni 2013
• David Pariser, Richard Scher, Boni Elewski, Phoebe Rich: Onychomycosis information for patients. Juni 2013

Boni Elizabeth Elewski, M.D.

Aktuelle Beschäftigung:

Beschäftigt als Programmleiterin an der Klinischen Fakultät der Medizinischen Hochschule an der Universität von Alabama in Birmingham, Abteilung für Dermatologie. Vormals Vorsitzende der Women’s Dermatology Society. Durchführung umfangreicher klinischer Studien im Fachbereich Dermatologie.

Fachgebiete:

Akne, Ekze, Pilzinfektionen, Dermatitis, Onchymykose, Haarausfall/Alopezie, Pilzinfektionen der Haut, Psoriasis

Veröffentlichungen:

• Boni E Elewski, Phoebe Rich, Richard Pollak, David M Pariser, Shinichi Watanabe, Hisato Senda, Chikara Ieda, Kathleen Smith, Radhakrishnan Pillai, Tage Ramakrishna, Jason T Olin: Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013 Apr;68(4):600-608. doi: 10.1016/j.jaad.2012.10.013. Epub 2012 Nov 20.
• Wang C, Cantrell W, Canavan T, Elewski B.: Successful Treatment of Dermatophytomas in 19 Patients Using Efinaconazole 10% Solution.
• Boni E Elewski, Phoebe Rich, Antonella Tosti, Aditya Gupta: Onchomycosis: an overview. Juni 2013

Phoebe Rich, MD

Aktuelle Beschäftigung:

Praktizierende Hautärztin, klinische Professorin am Zentrum für Dermatologie und Forschung Oregon (Oregon Dermatology and Research Center), Oregon Health & Science University, Portland.

Fachgebiete:

Dermatologie, Hautchirurgie, Erkrankungen der Nägel. Hauptverantwortliche für mehr als 400 klinische Studien

Veröffentlichungen:

• Boni Elewski, Phoebe Rich, George Han, Richard K. Scher, Abby Jacobson: Efficacy of brodalumab in total clearance of nail unit psoriasis. Dezember 2020
• Boni ElewskiPhoebe RichJohn W. BaddleyAtul DeodharMarina Magrey: Consistent scalp psoriasis clearance with mirikizumab maintenance treatment at 104 weeks in patients who had less than PASI 90 response at week 16: A phase 2 study analysis. Dezember 2020
• Phoebe Rich, Orin Goldblum, Damon Disch, Chen-Yen Lin, Joseph F. Merola: Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis. August 2020
• Matilde Iorizzo, Antonella Tosti, Michela Starace, Robert Baran, C Ralph Daniel: Isolated Nail Lichen Planus– an expert consensus on treatment of the classical form. Februar 2020
• Phoebe Rich, Mary Spellman, Vivek Purohit, Chuanbo Zang, Tim J. Crook: Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus. Februar 2019

Joel M Gelfand

Aktuelle Beschäftigung:

Professor für Dermatologie, Perelman School of Medicine, Universität Pennsylvania.

Fachgebiete:

            Dermatologie

Veröffentlichungen:

• Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB: The risk of myocardial infarction in patients with psoriasis. Journal of the American Medical Association 296: 1735-1741, 2006
• Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB: The risk of lymphoma in patients with psoriasis. Journal of Investigative Dermatology 126: 2194-2201, 2006.
• Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T: Epidemiology of Psoriatic Arthritis in the United States Population. Journal of the American Academy of Dermatology 53: 573-7, 2005
• Gelfand JM, Dommasch E, Shin DB, Azfar RS, Kurd SK, Wang X, Troxel AB: The Risk of Stroke in Patients with Psoriasis. Journal of Investigative Dermatology 129: 2411-2418, 2009.
• Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM: Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using General Practice Research Database. European Heart Journal 31: 1000-06, 2010.
• Dommasch, ED, Abuabara, K, Shin, DB, Nguyen, J, Troxel, AB, Gelfand JM: The Risk of Infection and Malignancy with Tumor Necrosis Factor Antagonists in Adult Patients with Psoriatic Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of the American Academy of Dermatology 64(6): 1035-1060, Juni 2011.
• Mehta N, Yu YD, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, Baer A, Antigua J, Van Voorhees AS, Torigian DA, Alavi A, Gelfand JM: Systemic and Vascular Inflammation in Patients with Moderate to Severe Psoriasis as measured by [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT): A Pilot Study. Archives of Dermatology 147(9): 1031-1039, September 2011.
• Langan SM, Seminara, NM, Shin, DB, Troxel A, Kimmel SE, Mehta NN, Margolis DJ, Gelfand JM: Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom. Journal of Investigative Dermatology Advance Online Publication, November 2011.
• Gelfand JM, Wan J, Callis Duffin, K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Bebo BF, Troxel AB, Shin DB, Steinemann JM, Goldfarb J, Yeung H, Van Voorhees AS: Comparative Effectiveness of Commonly Used Systemic Treatments or Phototherapy for Moderate to Severe Plaque Psoriasis in the Clinical Practice Setting. Archives of Dermatology 148(4): 487-94, April 2012.
• Mehta NN, Torigian DA, Gelfand, JM, Saboury, B, Alavi A: Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography (PET)/Computed Tomography (CT). Journal of Visualized Experiments 63: e3777, 2012.
• Azfar AS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM: Increased Risk of Diabetes and Likelihood of Receiving Diabetes Treatment in Patients with Psoriasis. Archives of Dermatology 18: 1 – 6. Juni 2012.
• Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Kreuger GG, Kalb RE, Weisman JD, Sperber BR, Brod BA, Bebo F, Schleicher SM, Shin DB, Troxel AB, Gelfand JM.: „Patient reported reasons for the discontinuation of commonly used treatments for moderate-to-severe psoriasis.“ Journal of American Academy of Dermatology 68: 64-72, 2013.

Alicia Bucko, D.O., J.D.

Aktuelle Beschäftigung:

Medizinische Leiterin des Academic Dermatology Associates, Albuquerque, New Mexico.

Fachgebiete:

            Dermatologie

Veröffentlichungen:

• Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, Herz-Ruelas ME, Jones TM, Jarratt MT, Pollak RA, Zane LT: The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis. J Drugs Dermatol. Sept. 2014;13(9):1124-32.
• Poulin Y, Sanchez NP, Bucko A, Fowler J, Jarratt M, Kempers S, Kerrouche N, Dhuin JC, Kunynetz R: A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial. Br J Dermatol. Juni 2011;164(6):1376-82.
• Rich P, Scher RK, Breneman D, Savin RC, Feingold DS, Konnikov N, Shupack JL, Pinnell S, Levine N, Lowe NJ, Aly R, Odom RB, Greer DL, Morman MR, Bucko AD, Tschen EH, Elewski BE, Smith EB, Hilbert J: Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. J Am Acad Dermatol. Juni 1998;38(6 Pt 2): S. 103-9.
• Scher RK, Breneman D, Rich P, Savin RC, Feingold DS, Konnikov N, Shupack JL, Pinnell S, Levine N, Lowe NJ, Aly R, Odom RB, Greer DL, Morman MR, Bucko AD, Tschen EH, Elewski BE, Smith EB : Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. Juni 1998;38(6 Pkt 2): S. 77-86.
• Jarratt M, Jones T, Adelglass J, Bucko A, Pollak R, Roman-Miranda A, Olin JT, Swinyer L: Efficacy and safety of once-daily luliconazole 1% cream in patients ≥12 years of age with interdigital tinea pedis: a phase 3, randomized, double-blind,vehicle-controlled study. J Drugs Dermatol. Juli 2014;13(7):838-46.
• Pariser D, Bucko A, Fried R, Jarratt MT, Kempers S, Kircik L, Lucky AW, Rafal E, Rendon M, Weiss J, Wilson DC, Rossi AB, Ramaswamy R, Nighland M: Tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for treatment of acne vulgaris: morning/morning regimen is as effective and safe as morning/evening regimen. J Drugs Dermatol. Juli 2010;9(7):805-13.
• Moore A, Ling M, Bucko A, Manna V, Rueda MJ: Efficacy and Safety of Subantimicrobial Dose, Modified-Release Doxycycline 40 mg Versus Doxycycline 100 mg Versus Placebo for the treatment of Inflammatory Lesions in Moderate and Severe Acne: A Randomized, Double-Blinded, Controlled Study. J Drugs Dermatol. Juni 2015;14(6):581-6.
• Stein Gold LF, Jarratt MT, Bucko AD, Grekin SK, Berlin JM, Bukhalo M, Weiss JS, Berk DR, Chang-Lin JE, Lin V, Kaoukhov A: Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials.

J Drugs Dermatol. Mai 2016 1;15(5):553-61.

• Tschen EH, Bucko AD, Oizumi N, Kawabata H, Olin JT, Pillai R: Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study. J Drugs Dermatol. Februar 2013;12(2):186-92.

Joachim Kresken, Dr.

Aktuelle Beschäftigung:

            Vorsitzender der GD Gesellschaft für Dermopharmazie e. V.

Fachgebiete:

            Dermatologie, Rosacea, Nagelpilz

Veröffentlichungen:

• Thomas L Diepgen, Joachim Kresken, Jean Krutmann, Rolf-Markus Szeimies: Commentary on the „Evidence- and Consensus-Based (S3) Guidelines for the Treatment of Actinic Keratosis“ Published by the International League of Dermatological Societies in Cooperation with the European Dermatology Forum. Apr 2018
• Joachim Kresken, Ursula Kindl, Walter Wigger-Alberti, Markus Reinholz: Dermocosmetics for Use in Rosacea: Guideline of the Society for Dermopharmacy. März 2018
• Thomas L Diepgen, J. Kresken, J. Krutmann, R.M. Szeimies: Kommentar zu den von der International League of Dermatological Societies (ILDS) in Kooperation mit dem European Dermatology Forum (EDF) herausgegeben „Evidence and consensus based (S3) Guidelines for the Treatment of Actinic Keratosis”. April 2016

Harald Bresser, Dr. med

Aktuelle Beschäftigung:

            Niedergelassener Facharzt, Hautarzt

Fachgebiete

            Dr. Bresser ist Facharzt für Dermatologie, Venerologie und Anästhesiologie.

Veröffentlichungen

Laser gegen Nagelpilz, https://www.drbresser.de/haende-und-fuesse/laserbehandlung-bei-nagelpilz/

Laurent Eckert

Aktuelle Beschäftigung:

            Beschäftigt bei Sanofi, Paris

Fachgebiete

            Dermatologie, atopische Dermatitis

Veröffentlichungen

• Lawrence F Eichenfield, Jonathan I Silverberg, Abhijit Gadkari, Karli Rosner: 15013 Dupilumab improves signs, symptoms, and quality of life in adolescents with moderate to severe atopic dermatitis. Dezember 2020
• Stephan Weidinger, Eric L. Simpson, Laurent Eckert, Abhijit Gadkari: 15115 The patient-reported disease burden in pediatric patients with atopic dermatitis: A cross-sectional study in the United States, Canada, Europe, and Japan. Dezember 2020
• Sebastien Barbarot, Jonathan I Silverberg, Abhijit Gadkari, Laurent Eckert: 15021 The family impact of atopic dermatitis in children aged 6-11 years: A cross-sectional study in the United States, Canada, Europe, and Japan. Dezember 2020
• Jonathan I Silverberg, Benjamin Lockshin, Melinda Gooderham, Ana Beatris Rossi: 15416 Long-term effect of dupilumab with concomitant topical corticosteroids on the Patient-Oriented Eczema Measure in Adults with moderate to severe atopic dermatitis: LIBERTY AD CHRONOS trial. Dezember 2020
• Eric L. Simpson, Mohamed Ahmed Kamal, John Douglas Davis, Ashish Bansal: 14148 Pharmacokinetics, safety, and efficacy of dupilumab in children aged ≥2 to. Dezember 2020
• Jonathan I Silverberg, Abhijit Gadkari, Eric L. Simpson, Laurent Eckert: 15112 Epidemiology of atopic dermatitis in children aged 6-11 years: A cross-sectional Study in the United States, Canada, Europe, and Japan. Dezember 2020
• Marjolein de Bruin-Weller, Mette Deleuran, Eric L. Simpson, Paola Mina-Osorio: 15117 Quality of life impact in adolescent patients with moderate to severe atopic dermatitis: Screening data from the LIBERTY AD ADOL trial. Dezember 2020
• Jonathan I Silverberg, Eric L Simpson, Emma Guttman-Yassky, Abhijit Gadkari: Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials. November 2020
• A S Paller, E C Siegfried, E L Simpson, A Bansal: A phase 2, open-label study of single dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. September 2020
• A. Beck, Jonathan I Silverberg, E.L. Simpson, A. Gadkari: Dupilumab Significantly Improves Sleep Outcomes in Adult Patients with Atopic Dermatitis: Results from Five Randomized Clinical Trials. August 2020
• Marjolein de Bruin-Weller, Eric L. Simpson, Michael Cork, Gaëlle Bégo-Le Bagousse: Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials. Juni 2020
• Jonathan I Silverberg, Gil Yosipovitch, Eric L. Simpson, Abhijit Gadkari: Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. März 2020
• Margitta Worm, Eric L. Simpson, Diamant Thaçi, Marius Ardeleanu: Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. Dezember 2019
• Amy S. Paller, Ashish Bansal, Eric L. Simpson, Abhijit Gadkari: Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Dezember 2019
• G Girolomoni, A Gadkari, S Auziere, Laurent Eckert: The Patient-Reported Disease Burden In Adults With Atopic Dermatitis: A Cross-Sectional Study In Canada and Europe. Oktober 2017
• Laurent Eckert, Shaloo Gupta, Caroline Amand, Joel M Gelfand: The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey. Oktober 2017

Eric L. Simpson, MD, MCR

Aktuelle Beschäftigung:

Professor für Dermatologie, Leiter der klinischen Forschungsabteilung der Health & Science University Oregon,

Fachgebiete

            Dermatologie, atopische Dermatitis

Veröffentlichungen

• Eichner, B., Michaels, L. A. C., Branca, K., Ramsey, K., Mitchell, J., Morris, C. D., Fagnan, L. J., Dolor, R. J., Elder, N., Hahn, D. L., Nease, D. E., Lapidus, J., Cibotti, R., Block, J. & Simpson, E. L.: A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE): An atopic dermatitis primary prevention study using emollients – Protocol for a randomized controlled trial. 4. März 2020, In: Trials. 21, 1, 243.
• Igelman, S. J., Na, C. & Simpson, E. L.: Alcohol-induced facial flushing in a patient with atopic dermatitis treated with dupilumab. Feb 2020, In: JAAD Case Reports. 6, 2, p. 139-140 2 p.
• Paller, A. S., Siegfried, E. C., Simpson, E. L., Cork, M. J., Lockshin, B., Kosloski, M. P., Kamal, M. A., Davis, J. D., Sun, X., Pirozzi, G., Graham, N. M. H., Gadkari, A., Eckert, L., Ruddy, M. & Bansal, A.: A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. 2020, (Accepted/In press) In: Journal of the European Academy of Dermatology and Venereology.
• Gelfand, J. M., Shin, D. B., Duffin, K. C., Armstrong, A. W., Blauvelt, A., Tyring, S. K., Menter, A., Gottlieb, S., Lockshin, B. N., Simpson, E. L., Kianifard, F., Sarkar, R. P., Muscianisi, E., Steadman, J., Ahlman, M. A., Playford, M. P., Joshi, A. A., Dey, A. K., Werner, T. J., Alavi, A.: A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). Sep 2020, In: Journal of Investigative Dermatology. 140, 9, p. 1784-1793.e2
• Sonja Ständer, Eric L. Simpson, Emma Guttman-Yassky, Jacob P. Thyssen, Kenji Kabashima, Susan G. Ball, Maria Jose Rueda, Amy M. DeLozier, Jonathan I. Silverberg: Clinical Relevance of Skin Pain in Atopic Dermatitis. 1. Oktober 2020, In: Journal of drugs in dermatology : JDD. 19, 10, p. 921-926 6 p.